| Filed On | Filing |
|---|---|
| 04 Nov 2026 |
8-K: Other Events
Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War |
| 02 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
GAITHERSBURG, Md., November 2, 2026—Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the third quarter ended September 30, 2026. |
| 16 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
GAITHERSBURG, Md., October 16, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that Richard S. Lindahl, executive vice president, chief financial officer, will retire from the Company effective December 31... |
| 14 Sep 2026 |
8-K: Regulation FD Disclosure
1 September 14, 2026 Combating Public Health Threats for Communities Around the World Joe Papa President and Chief Executive Officer H.C. Wainwright 28th Annual Global Investment Conference |
| 01 Sep 2026 |
8-K: Other Events
Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities +2 more
GAITHERSBURG, Md., August 5, 2026—Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2026. |
| 29 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government |
| 30 Apr 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
GAITHERSBURG, Md., April 30, 2026—Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended March 31, 2026. |
| 30 Apr 2026 |
8-K: Submission of Matters to a Vote of Security Holders
EMERGENT BIOSOLUTIONS INC. AMENDED AND RESTATED STOCK INCENTIVE PLAN 1. Purpose The purpose of this Amended and Restated Stock Incentive Plan (the “Plan”) of Emergent BioSolutions Inc., a Delaware corporation (the “Company”), is to advan... |
| 17 Apr 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +2 more
Exhibit 10.2 AMENDMENT NO. 1 TO CREDIT AGREEMENT This AMENDMENT NO. 1 TO CREDIT AGREEMENT (this “Amendment”), dated as of April 16, 2026 (the “Amendment No. 1 Effective Date”), is entered into by and among EMERGENT BIOSOLUTIONS INC., a D... |
| 03 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
GAITHERSBURG, Md., March 3, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of John D. Fowler, Jr. to its board of directors effective March 1, 2026. Mr. Fowler brings more than three decad... |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
GAITHERSBURG, Md., February 26, 2026—Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2025. |
| 14 Jan 2026 |
8-K: Regulation FD Disclosure
Exhibit 99.1 Combating Public Health Threats for Communities Around the World th 44 Annual J.P. Morgan Healthcare Conference Joe Papa President and Chief Executive Officer January 14, 2026 1 1 |
| 12 Jan 2026 |
8-K: Regulation FD Disclosure
Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation |
| 12 Dec 2025 |
8-K: Regulation FD Disclosure
Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site |
| 12 Nov 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
GAITHERSBURG, Md., November 12, 2025 (GLOBE NEWSWIRE) – Emergent BioSolutions (NYSE: EBS) announced today that Dr. Louis W. Sullivan will retire from the company’s Board of Directors effective November 14 after 19 years of service to the... |
| 29 Oct 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
GAITHERSBURG, Md., October 29, 2025—Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the third quarter ended September 30, 2025. |
| 11 Sep 2025 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness |
| 05 Sep 2025 |
8-K: Other Events
Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use |
| 06 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
GAITHERSBURG, Md., August 6, 2025—Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2025. |
Loading...